JPMorgan Chase & Co. Issues Positive Forecast for Heartflow (NASDAQ:HTFL) Stock Price

Heartflow (NASDAQ:HTFL) had its target price hoisted by JPMorgan Chase & Co. from $35.00 to $45.00 in a report published on Friday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other research analysts also recently commented on HTFL. Morgan Stanley raised their price objective on Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a report on Friday. Stifel Nicolaus upped their target price on Heartflow from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday. Weiss Ratings raised Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. Freedom Capital upgraded Heartflow to a “strong-buy” rating in a report on Tuesday, June 30th. Finally, Benchmark reaffirmed a “buy” rating on shares of Heartflow in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.43.

Heartflow Price Performance

Shares of HTFL opened at $42.08 on Friday. The firm has a market capitalization of $3.63 billion and a price-to-earnings ratio of -22.99. Heartflow has a 1-year low of $20.13 and a 1-year high of $43.00. The company has a 50-day moving average of $29.08 and a 200 day moving average of $27.80.

Heartflow (NASDAQ:HTFL) last issued its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.50%. The business had revenue of $64.08 million for the quarter. The business’s quarterly revenue was up 47.7% on a year-over-year basis. On average, equities analysts anticipate that Heartflow will post -0.82 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO John C.M. Farquhar sold 38,900 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $35.00, for a total value of $1,361,500.00. Following the completion of the transaction, the chief executive officer owned 457,935 shares of the company’s stock, valued at $16,027,725. The trade was a 7.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $28.34, for a total value of $261,266.46. Following the sale, the insider owned 78,731 shares of the company’s stock, valued at approximately $2,231,236.54. This represents a 10.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 115,805 shares of company stock valued at $3,530,609 in the last three months. 7.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Heartflow

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jupiter Topco LLC purchased a new position in Heartflow in the second quarter valued at about $70,983,000. Legal & General Group Plc bought a new stake in shares of Heartflow in the 2nd quarter valued at about $998,000. The Manufacturers Life Insurance Company purchased a new position in shares of Heartflow in the 2nd quarter worth approximately $1,142,000. Brandywine Managers LLC purchased a new position in shares of Heartflow in the 2nd quarter worth approximately $294,000. Finally, Quantbot Technologies LP bought a new position in shares of Heartflow during the 2nd quarter worth approximately $1,207,000.

Heartflow News Roundup

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Heartflow reported second-quarter revenue of $64.1 million, up 47.7% year over year, while its adjusted loss of $0.07 per share beat the consensus estimate of a $0.22 loss. The results also showed improving profitability, with adjusted EBITDA losses narrowing to $6.7 million from $10.1 million a year earlier. Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $246 million-$250 million from $228 million-$232 million, above the roughly $230 million analyst consensus, and projected non-GAAP gross margin of about 82%. HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance
• Positive Sentiment: Growth was supported by stronger U.S. FFRCT volume and increasing adoption of the Plaque product, suggesting Heartflow’s AI-based coronary disease platform is broadening beyond its core business.
• Positive Sentiment: Analysts raised their targets following the report: JPMorgan increased its target to $45 and Stifel raised its target to $45, with both firms maintaining bullish ratings. Wells Fargo also raised its target to $39 and retained an “overweight” rating. Analyst Price Target Updates
• Neutral Sentiment: The strong move pushed the stock near its 52-week high, potentially increasing volatility and making valuation a greater consideration for investors despite improving operating trends.
• Negative Sentiment: Insiders have reported repeated open-market sales, including a 22,562-share sale by CEO John C.M. Farquhar. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal, but continued insider selling may still weigh on sentiment. Heartflow CEO Sells Shares

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.